Komori
Shin Nippon Biomedical Laboratories (2395) · InitiativeAchieved

Tasso Self-Collection Blood Device Enters Japan

First written in FY2026-H1. 1 of 3 entries say "Advanced", first in 2026-05-11. Latest entry: FY2026.

3entries
2years
1from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseFirst statedFY2026-H1Advanced2026-05-11 – FY20262025: 120252026: 22026
Same theme, other companies
Japan Certification and Sales Launch of Tasso’s Self-Blood-Collection DeviceA theme 1 companies write about · 0 as a headwind · 1 as a tailwind

No other company in this theme has enough history to compare yet.

Full recordFilings, disclosures and news, newest first
  1. FY2026AchievedAnnual report

    「シアトル発の「自己採血デバイス」を手掛けるスタートアップ企業Tasso, Inc.とともに、2025年3月に合弁会社の(株)新日本科学Tassoを設立し、8月に厚生労働省から管理医療機器として認証を取得、12月から販売を開始しました。2026年3月にはH.U.グループ傘下の企業と販売店契約を締結しております。」

    Tassoの日本展開について、合弁会社設立・管理医療機器認証取得に続き、2025年12月の販売開始と2026年3月の販売店契約締結に至った。
  2. 2026-05-11AdvancedEarnings

    「In August, we obtained certification from the Ministry of Health, Labour and Welfare as a controlled medical device and began sales in December. In March 2026, we entered into a distributor agreement with a company under H.U. Group.」

    Tasso's expansion in Japan progressed from obtaining certification and beginning sales to entering into a distributor agreement.
  3. FY2026-H1First statedAnnual report

    「また、米国シアトル発の「自己採血デバイス」を手掛けるスタートアップ企業・Tasso, Inc.の日本進出については、2025年3月に合弁会社・新日本科学Tassoを設立し、8月に厚生労働省から管理医療機器として認証を取得、年内発売に向けて準備を進めています。」

    Tasso社の自己採血デバイスについて、2025年3月の合弁会社設立、8月の管理医療機器認証取得、年内発売準備という日本展開を初めて示した。
Moved together

"A Global Value Chain Spanning Japan, the United States and Asia" moved the same way as this thread, in the same document, in 2 of its 3 moves.

222222★123456
  1. ★This thread
  2. 1A Global Value Chain Spanning Japan, the United States and Asia2×
  3. 2Expanding Contracted Services through Strategic Alliances2×
  4. 3Advanced Evaluation Facilities and Disease Models for Antibody Medicines and Regenerative Medicine2×
  5. 4Supporting Japanese and U.S. Market Entry through SNBL Global Gateway2×
  6. 5Addressing Environmental and Social Issues to Achieve ESG and the SDGs2×
  7. 6A Paradigm Shift from Contract Services to Drug-Discovery-Oriented Pharmaceutical Development Support2×

★ is this thread; numbers match the list above. The number on a line is how many documents both moved the same way in; lines between the other threads count the documents they moved together in too. Threads that move together often sit closer.

When this could move next
Shin Nippon Biomedical Laboratories's next results are scheduled for 2026-11-10. Read the earnings preview It last moved in the Earnings of 2026-05-11: "Advanced".
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.